1,8-二氮杂螺[4.5]癸-2-酮盐酸盐 | 1389313-57-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂螺癸烷衍生物
• 中文名称: 1,8-二氮杂螺[4.5]癸-2-酮盐酸盐
• 英文名称: 1,8-diazaspiro[4.5]decan-2-one hydrochloride
• 英文别名: 1,8-diazaspiro[4.5]decan-2-one;hydrochloride
• CAS: 1389313-57-8
• 化学式: C₈H₁₄N₂O*ClH
• 分子量: 190.673
• InChiKey: LRICLOKLOIFZFZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.44
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  41.1
• 氢给体数：
  3
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  1,8-二氮杂螺[4.5]癸-2-酮盐酸盐 在 ammonium hydroxide 、 tris-(dibenzylideneacetone)dipalladium(0) 、 4,5-双二苯基膦-9,9-二甲基氧杂蒽 、 sodium t-butanolate 作用下， 以 甲苯 为溶剂， 反应 5.0h， 生成 8-(6-((9-((1r,4r)-4-methylcyclohexyl)-9H-pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidin-2-yl)amino)pyridin-3-yl)-1,8-diazaspiro[4.5]decan-2-one
  参考文献：
  名称：

  Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3

  摘要：

  We describe the structural optimization of a lead compound 1 that exhibits dual inhibitory activities against FLT3 and CDK4. A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivatives was synthesized, and SAR analysis, using cell-based assays, led to the discovery of 28 (AMG 925), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date. Compound 28 inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3(WT)) and induced cell death in MOLM13 (FLT3(ITD)) and even in MOLM13 (FLT3(ITD, D835Y), which exhibits resistance to a number of FLT3 inhibitors currently under clinical development. At well-tolerated doses, compound 28 leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.

  DOI：

  10.1021/jm500118j
• 作为产物：
  描述：

  2-氧代-1,8-二氮杂螺[4.5]癸烷-8-羧酸叔丁酯 在 盐酸 作用下， 以 1,4-二氧六环 为溶剂， 反应 2.0h， 以100%的产率得到1,8-二氮杂螺[4.5]癸-2-酮盐酸盐
  参考文献：
  名称：

  Discovery of AMG 925, a FLT3 and CDK4 Dual Kinase Inhibitor with Preferential Affinity for the Activated State of FLT3

  摘要：

  We describe the structural optimization of a lead compound 1 that exhibits dual inhibitory activities against FLT3 and CDK4. A series of pyrido[4',3':4,5]pyrrolo[2,3-d]pyrimidine derivatives was synthesized, and SAR analysis, using cell-based assays, led to the discovery of 28 (AMG 925), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date. Compound 28 inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb+) and U937 (FLT3(WT)) and induced cell death in MOLM13 (FLT3(ITD)) and even in MOLM13 (FLT3(ITD, D835Y), which exhibits resistance to a number of FLT3 inhibitors currently under clinical development. At well-tolerated doses, compound 28 leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.

  DOI：

  10.1021/jm500118j

文献信息

• [EN] COMPOUNDS FOR INHIBITING LRRK2 KINASE ACTIVITY<br/>[FR] COMPOSÉS POUR INHIBER L'ACTIVITÉ KINASE LRRK2
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2018137618A1

  公开（公告）日：2018-08-02

  Compounds of Formula (I) or pharmaceutically acceptable salt thereof, a pharmaceutical compositions comprising these compounds, the use of these compounds and compositions in the treatment of diseases in which LRRK-2 kinase is involved.

  公式(I)的化合物或其药用可接受盐，包含这些化合物的药物组合物，以及这些化合物和组合物在治疗LRRK-2激酶参与的疾病中的用途。
• [EN] PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA<br/>[FR] INHIBITEURS PURIQUES DE LA PHOSPHATIDYLINOSITOL 3-KINASE DELTA HUMAINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2019119207A1

  公开（公告）日：2019-06-27

  Provided are compounds of formula (I) which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.

  提供的是式（I）的化合物，它们是PI3K-δ抑制剂，因此可用于治疗由PI3K-δ介导的疾病，如炎症、哮喘、慢性阻塞性肺病和癌症。
• SUBSTITUTED PYRIDINE AND PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US20190308950A1

  公开（公告）日：2019-10-10

  Substituted pyrimidine and pyridines as NR2B receptor ligands. Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  用嘧啶和吡啶替代作为NR2B受体配体。这些化合物可用于NR2B受体调节以及用于治疗由NR2B受体活性介导的疾病状态、紊乱和病况的药物组合物和方法。
• Compounds
  申请人：GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED

  公开号：US10858367B2

  公开（公告）日：2020-12-08

  Provided are novel compounds that inhibit LRRK2 kinase activity, processes for their preparation, compositions containing them and their use in the treatment of or prevention of diseases associated with or characterized by LRRK2 kinase activity, for example Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

  本文提供了抑制 LRRK2 激酶活性的新型化合物、其制备工艺、含有这些化合物的组合物以及它们在治疗或预防与 LRRK2 激酶活性相关或以 LRRK2 激酶活性为特征的疾病（例如帕金森病、阿尔茨海默病和肌萎缩性脊髓侧索硬化症 (ALS)）中的用途。
• Substituted pyridine and pyrimidines and their use as GluN2B receptor modulators
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：US11008302B2

  公开（公告）日：2021-05-18

  Substituted pyrimidine and pyridines as NR2B receptor ligands, for example Such compounds may be used in NR2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by NR2B receptor activity.

  作为 NR2B 受体配体的取代嘧啶和吡啶，例如 这类化合物可用于 NR2B 受体调节以及治疗由 NR2B 受体活性介导的疾病状态、失调和病症的药物组合物和方法中。